Repository logo
 
Publication

Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure

dc.contributor.authorLópez Mínguez, JR
dc.contributor.authorAsensio, JM
dc.contributor.authorGragera, JE
dc.contributor.authorCosta, MA
dc.contributor.authorGonzález, IC
dc.contributor.authorde Carlos, FG
dc.contributor.authorDíaz, JA
dc.contributor.authorMartín Yuste, V
dc.contributor.authorGonzález, RM
dc.contributor.authorDomínguez-Franco, A
dc.contributor.authorBuendía, AB
dc.contributor.authorGaribi, JH
dc.contributor.authorHernández, FH
dc.contributor.authorRibeiro, VG
dc.date.accessioned2016-05-11T16:40:01Z
dc.date.available2016-05-11T16:40:01Z
dc.date.issued2015-06
dc.description.abstractAIMS: The aim of this study was to observe the percentage of thromboembolic and haemorrhagic events over a 2-year follow-up in patients with non-valvular atrial fibrillation (NVAF) undergoing closure of the left atrial appendage (LAA) with an occlusion device. Observed events and CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke history), CHA2DS2-VASc (also adding: vascular disease and sex) and HAS-BLED (hypertension, abnormal liver/renal function, stroke history, bleeding predisposition, labile international normalised ratios, elderly, drugs/alcohol use)-predicted events were compared. METHODS: LAA closure with an occlusion device was performed in 167 NVAF patients contraindicated for oral anticoagulants and recruited from 12 hospitals between 2009 and 2013. At least two transoesophageal echocardiograms were performed in the first 6 months postimplantation. Antithrombotics included clopidogrel and aspirin. Patients were monitored for death, stroke, major and relevant bleeding and hospitalisation for concomitant conditions. Mean age was 74.68±8.58, median follow-up was 24 months, 5.38% had intraoperative complications and implantation was successful in 94.6% of subjects. Mortality during follow-up was 10.8%, mostly (9.5%) non-cardiac related. Bleeding occurred in 10.1% of subjects, 5.7% major and 4.4% minor though relevant, and 4.4% suffered stroke. Major bleeding and stroke/transient ischaemic attack events within 2 years (annual event rates, 290 patients/year) were less frequent than expected from CHADS2 (2.4% vs 9.6%), CHA2DS2-VASc (2.4% vs 8.3%) and HAS-BLED (3.1% vs 6.6%) risk scores (p<0.001, p=0.003, p=0.047, respectively). CONCLUSIONS: LAA closure with an occlusion device in patients contraindicated for oral anticoagulants is a therapeutic option associated with fewer thromboembolic and haemorrhagic events than expected from risk scores, particularly in the second year postimplantation.pt_PT
dc.identifier.citationHeart. 2015 Jun;101(11):877-83.pt_PT
dc.identifier.doi10.1136/heartjnl-2014-306332pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.4/1905
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectFibrilhação Auricularpt_PT
dc.subjectApêndice Auricularpt_PT
dc.subjectOclusão Terapêuticapt_PT
dc.titleTwo-year clinical outcome from the Iberian registry patients after left atrial appendage closurept_PT
dc.typejournal article
dspace.entity.typePublication
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Heart.pdf
Size:
436.14 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections